eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-2.17 |
-2.16 |
0.01 |
0.46% |
2024-03-25 |
2023-12 |
-2.73 |
N/A |
N/A |
N/A |
2024-03-25 |
2023-12 |
-2.73 |
-3.42 |
-0.69 |
-25.27% |
2023-11-13 |
2023-09 |
-3.25 |
-3.25 |
N/A |
N/A |
2023-11-13 |
2023-09 |
-3.25 |
N/A |
N/A |
N/A |
2023-08-08 |
2023-06 |
-4.75 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-23 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-05-25 |
Stifel |
Upgrade |
Hold |
Buy |
2023-05-09 |
Credit Suisse |
Upgrade |
|
Outperform |
2023-03-08 |
Credit Suisse |
Upgrade |
|
Outperform |
2023-01-08 |
JMP Securities |
Upgrade |
|
Market Outperform |
2023-01-05 |
Credit Suisse |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2021-08-24 |
BHATT ELIZABETH |
Director |
0.00 |
Conversion of Exercise of derivative security |
2023-11-14 |
BYRNES MICHAEL |
Chief Financial Officer |
43.27K |
Stock Award(Grant) |
2022-10-03 |
EHRLICH CHRISTOPHER B |
Director |
178.42K |
Purchase |
2022-06-22 |
GALLAGHER BRIAN M JR. |
Director |
30.00K |
Purchase |
2022-08-02 |
PRESIDIO MANAGEMENT GROUP X L L C |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2021-12-01 |
ROOT JONATHAN D |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
SR One Capital Management, LP |
6.82M |
5.66M |
11.05% |
2023-06-29 |
Carlyle Group Inc. |
4.82M |
4.00M |
7.81% |
2023-06-29 |
Column Group LLC |
4.31M |
3.58M |
6.98% |
2023-06-29 |
Sectoral Asset Management, Inc. |
2.38M |
1.98M |
3.86% |
2023-06-29 |
Parallel Advisors, LLC |
1.69M |
1.41M |
2.74% |
2023-06-29 |
Blackstone Inc |
1.31M |
1.09M |
2.12% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
300.03K |
249.09K |
0.49% |
2023-06-29 |
Vanguard Extended Market Index Fund |
94.45K |
78.41K |
0.15% |
2023-05-30 |
Fidelity Extended Market Index Fund |
55.53K |
51.64K |
0.09% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
24.01K |
22.32K |
0.04% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
10.55K |
9.81K |
0.02% |
2023-05-30 |
Fidelity Total Market Index Fund |
9.49K |
8.82K |
0.02% |
Split |
Date |
1 : 25 |
2024-01-12 |